Clinical Research


 

Celiac Disease

INOVATE A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Larazotide for Relief of Persistent Symptoms in Patients with Celiac Disease on a Gluten Free Diet
 

Crohn’s Disease

ADVANCE: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Cronh’s Disease

U-EXCEED: A Multicenter, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy

U-EXCEL: A Multicenter, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy

DIVERSITY Combined Phase 3, Double-blind, Randomized, Placebo‑Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

DIVERGENCE 1 A Phase 2, Double-Blind, Randomized, Placebozontrolled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatnent of Small Bowel Crohn's Disease (SBCD)

DIVERGENCE 2 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
 

Fatty Liver

NASH A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis

Ulcerative Colitis

U-ACCOMPLISH: A Multicenter, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis

U-ACHIEVE:  A Multicenter, Double-Blind, Placebo-Controlled Induction Study of the Safety and Efficacy of ABT – 494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

VIBRATO: A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651660 and PF-06700841 As Induction and Chronic Therapy in Subjects with Moderate to Severe Ulcerative Colitis 

MANTA A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease

Our Locations

Choose your preferred location